Five reasons the TRIPS waiver should not be expanded to covid therapeutics
An expanded waiver would derail current successful efforts to expand access to Covid treatments and destroy innovation incentives
Executive Director
Philip founded Geneva Network in 2015. His main research interests are the intersection of intellectual property, trade, and health policy. Formerly he was an official at the World Intellectual Property Organization (WIPO) in Geneva, where he worked in its Global Challenges Division on a range of IP and health issues. Prior to his time with WIPO, Philip worked as director of policy for International Policy Network, a UK-based think tank, as well as holding research positions with the Adam Smith Institute and Reform, both in London. He has also worked as a political risk consultant and a management consultant. He is a regular columnist in a wide range of international newspapers and has published a number of academic studies. He holds degrees from the London School of Economics and Durham University (UK). He is also a Senior Fellow at the Institute for Democracy and Economic Affairs, Malaysia.
Criação de um sistema de patentes previsível e estável no Brazil
Nossa agenda de reformas para atualizar o sistema brasileiro de exame de patentes para padrões internacionais.
Building a predictable, stable patent system in Brazil
Our reform agenda to upgrade the Brazilian patent examination system to international standards.
The role of intellectual property rights in preparing for future pandemics
Even though IP has played a crucial role in developing and manufacturing vaccines for the current pandemic, some are calling for IP to be waived to facilitate preparations for future pandemics.
Why protect Biopharma regulatory data?
An important intellectual property right that can drive investment into Gulf cooperation council countries.
Patent linkage in the Gulf Cooperation Council
The promise of patent linkage Robust intellectual property (IP) protection is vital for biopharmaceutical innovation....
لماذا يجب حماية البيانات التنظيمية للصناعات الدوائية؟
Conclusion Considerations of the cost of RDP must also be weighed against the benefits that…
Why waiving intellectual property rights for Covid vaccines is wrong
The UK, EU and other allies should speak out against the badly thought out proposal before the WTO.
IP rights are the key to Covid-19 vaccines
The intellectual property system has continually confounded its critics in the Covid crisis, providing a framework for vaccine innovation and rapid manufacturing scale-up.